Page last updated: 2024-12-10

trans-2,3',4,5'-tetrahydroxystilbene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

trans-2,3',4,5'-tetrahydroxystilbene: hydroxystilbene oxyresveratrol [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5281717
CHEMBL ID43065
CHEBI ID7870
SCHEMBL ID501690
MeSH IDM0504227

Synonyms (76)

Synonym
AC-5279
4-[2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,3-diol
ACON1_001063
tetrahydroxystilbene
nsc-315550
4721-07-7
nsc315550
MEGXP0_001057
oxyresveratrol ,
29700-22-9
2,3',4,5'-tetrahydroxystilbene
4-[(e)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,3-diol
NCGC00169713-01
LMPK13090011
chebi:7870 ,
CHEMBL43065 ,
trans-2,4,3',5'-tetrahydroxystilbene
MLS002473086
smr001397189
n.357
trans-2,4,3'',5''-tetrahydroxystilbene
bdbm50108046
cid_5281717
(oxyresveratrol)4-[(e)-2-(3,5-dihydroxyphenyl)vinyl]benzene-1,3-diol
O0373
2,3',4,5'-tetrahydroxy-trans-stilbene
4-[(e)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,3-diol
A820013
HMS2218H19
puag-haad
2,4,3',5'-tetrahydroxystilbene
1,3-benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-
nsc 315550
S4739
hydroxyresveratrol
unii-6v071cp5cr
6v071cp5cr ,
o-res cpd
1,3-benzenediol, 4-(2-(3,5-dihydroxyphenyl)ethenyl)-, (e)-
REGID_FOR_CID_658108
AKOS015915071
oxyresvenox
trans-stilbene-2,4,3',5'-tetrol
2,3',4,5'-stilbenetetrol, (e)-
hydroxyresveratrol [inci]
trans-2,3',4,5'-tetrahydroxystilbene
1,3-benzenediol, 4-((1e)-2-(3,5-dihydroxyphenyl)ethenyl)-
oxylresveratrol
REGID_FOR_CID_5281717
(e)-5,5'-(ethene-1,2-diyl)bis(benzene-1,3-diol)
J-501984
SCHEMBL501690
(e)-4-(3,5-dihydroxystyryl)benzene-1,3-diol
1,3-benzenediol, 4-[(1e)-2-(3,5-dihydroxyphenyl)ethenyl]-
oxyresveratrol, >=97.0% (hplc)
mfcd11974969
CS-5655
HY-N1430
ncgc00169713-02!4-[(e)-2-(3,5-dihydroxyphenyl)ethenyl]benzene-1,3-diol
4-(3,5-dihydroxystyryl)benzene-1,3-diol
PDHAOJSHSJQANO-OWOJBTEDSA-N
trans-oxyresveratrol
EZE ,
BCP24308
Z2311627398
3' 4 5'-tetrahydroxystilbene
AS-35032
Q7116143
HMS3885N20
CCG-266904
NCGC00169713-02
4-(2-(3,5-dihydroxyphenyl)ethenyl)benzene-1,3-diol
DTXSID801030442
EN300-18754447
GLXC-19085
EN300-7368059

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The validated method was used to study the pharmacokinetic profiles of OXY and RES in rat plasma after oral administration of Smilax china root extract."( High performance liquid chromatographic method for the determination and pharmacokinetic studies of oxyresveratrol and resveratrol in rat plasma after oral administration of Smilax china extract.
Chen, G; Guo, DA; Huang, H; Li, P; Lu, Z; Sha, N; Shao, B; Wang, X; Zhang, J, 2008
)
0.35
" After intravenous administration, OTE possessed a long terminal elimination half-life (t(1/2) (λz) = 481 ± 137 min) and slow clearance (Cl = 29."( Quantification of oxyresveratrol analog trans-2,4,3',5'-tetramethoxystilbene in rat plasma by a rapid HPLC method: application in a pre-clinical pharmacokinetic study.
Choo, QY; Ho, PC; Lin, HS, 2010
)
0.36
" This study examined the determining factors for previously reported oral pharmacokinetic profiles of MulA and its bacterial metabolite oxyresveratrol (OXY) on in vitro models."( In vitro pharmacokinetic characterization of mulberroside A, the main polyhydroxylated stilbene in mulberry (Morus alba L.), and its bacterial metabolite oxyresveratrol in traditional oral use.
Lei, JP; Mei, M; Ruan, JQ; Wang, YT; Wu, WJ; Yan, R; Zhao, HY; Zhou, RN, 2012
)
0.38
" However, there is limited pharmacokinetic information on this compound, especially its distribution in neuronal tissue and its route of excretion."( Comparative pharmacokinetics of oxyresveratrol alone and in combination with piperine as a bioenhancer in rats.
Anukunwithaya, T; Junsaeng, D; Khemawoot, P; Likhitwitayawuid, K; Songvut, P; Sritularak, B, 2019
)
0.51
"The addition of piperine could enhance some of the pharmacokinetic properties of oxyresveratrol via both intravenous and oral administration."( Comparative pharmacokinetics of oxyresveratrol alone and in combination with piperine as a bioenhancer in rats.
Anukunwithaya, T; Junsaeng, D; Khemawoot, P; Likhitwitayawuid, K; Songvut, P; Sritularak, B, 2019
)
0.51
" However, the unfavorable pharmacokinetic properties of oxyresveratrol, including low water solubility and poor oral availability and stability, have posed challenges to its development as a useful therapeutic agent."( Oxyresveratrol: Sources, Productions, Biological Activities, Pharmacokinetics, and Delivery Systems.
Likhitwitayawuid, K, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
" The aim of this study was to investigate the pharmacokinetic profiles of oxyresveratrol alone and in combination with piperine as a bioenhancer in rats."( Comparative pharmacokinetics of oxyresveratrol alone and in combination with piperine as a bioenhancer in rats.
Anukunwithaya, T; Junsaeng, D; Khemawoot, P; Likhitwitayawuid, K; Songvut, P; Sritularak, B, 2019
)
0.51
"Male Wistar rats were administered with oxyresveratrol 10 mg/kg, oxyresveratrol 10 mg/kg plus piperine 1 mg/kg via intravenous or oxyresveratrol 100 mg/kg, oxyresveratrol 100 mg/kg plus piperine 10 mg/kg via oral gavage."( Comparative pharmacokinetics of oxyresveratrol alone and in combination with piperine as a bioenhancer in rats.
Anukunwithaya, T; Junsaeng, D; Khemawoot, P; Likhitwitayawuid, K; Songvut, P; Sritularak, B, 2019
)
0.51
"The combination with piperine had shown a significantly higher maximum concentration in plasma approximately 1500 μg/L within 1-2 h after oral dosing, and could increase oral bioavailability of oxyresveratrol approximately 2-fold."( Comparative pharmacokinetics of oxyresveratrol alone and in combination with piperine as a bioenhancer in rats.
Anukunwithaya, T; Junsaeng, D; Khemawoot, P; Likhitwitayawuid, K; Songvut, P; Sritularak, B, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
"The aim of this study was to develop and assess nanostructured lipid carriers (NLC) compared to solid lipid nanoparticles (SLN) for improving the oral bioavailability of oxyresveratrol (OXY)."( Modification of oral absorption of oxyresveratrol using lipid based nanoparticles.
Likhitwitayawuid, K; Sangsen, Y; Sritularak, B; Wiwattanapatapee, R; Wiwattanawongsa, K, 2015
)
0.42
"The combination with piperine had shown a significantly higher maximum concentration in plasma approximately 1500 μg/L within 1-2 h after oral dosing, and could increase oral bioavailability of oxyresveratrol approximately 2-fold."( Comparative pharmacokinetics of oxyresveratrol alone and in combination with piperine as a bioenhancer in rats.
Anukunwithaya, T; Junsaeng, D; Khemawoot, P; Likhitwitayawuid, K; Songvut, P; Sritularak, B, 2019
)
0.51
"Oxyresveratrol (OXY) exhibits poor bioavailability due to its low solubility."( Exploring potential coformers for oxyresveratrol using principal component analysis.
Hirun, N; Ouiyangkul, P; Tantishaiyakul, V, 2020
)
0.56
" Nevertheless, chemical instability and low solubility of OXY in aqueous solutions reduce its bioavailability and hinder it from exerting neuroprotective activities."( Alkoxy glycerol enhanced activity of Oxyresveratrol in Alzheimer's disease by rescuing Tau protein.
Elumalai, P; Lakshmi, S; Sivan, S; Varija Raghu, S, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" Compared to resveratrol, OXY exhibited a wider effective dosage range."( Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity.
Chang, RC; Chao, J; Ho, YS; Wang, M; Yu, MS, 2008
)
0.35
" The pharmacokinetics of OTE was assessed in rats using 2-hydroxypropyl-β-cyclodextrin as a dosing vehicle."( Quantification of oxyresveratrol analog trans-2,4,3',5'-tetramethoxystilbene in rat plasma by a rapid HPLC method: application in a pre-clinical pharmacokinetic study.
Choo, QY; Ho, PC; Lin, HS, 2010
)
0.36
"Potassium oxonate-induced hyperuricemic mice were dosed by gavage with eight stilbenes."( Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice.
Hong, Y; Kong, LD; Li, Z; Liu, L; Liu, YL; Shi, YW; Wang, CP; Wang, X, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (38)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency79.43280.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency14.12540.007215.758889.3584AID588342
acid sphingomyelinaseHomo sapiens (human)Potency25.118914.125424.061339.8107AID504937
BRCA1Homo sapiens (human)Potency35.48130.89137.722525.1189AID624202
ClpPBacillus subtilisPotency25.11891.995322.673039.8107AID651965
ATAD5 protein, partialHomo sapiens (human)Potency27.86460.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency17.35820.000811.382244.6684AID686978; AID686979
P53Homo sapiens (human)Potency22.38720.07319.685831.6228AID504706
IDH1Homo sapiens (human)Potency18.35640.005210.865235.4813AID686970
importin subunit beta-1 isoform 1Homo sapiens (human)Potency2.31095.804836.130665.1308AID540253
snurportin-1Homo sapiens (human)Potency2.31095.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency2.31095.804816.996225.9290AID540253
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency11.22020.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency11.22020.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency11.22020.15855.287912.5893AID540303
VprHuman immunodeficiency virus 1Potency31.62281.584919.626463.0957AID651644
Alpha-synucleinHomo sapiens (human)Potency14.12540.56239.398525.1189AID652106
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phosphotyrosine protein phosphatase Mycobacterium tuberculosisIC50 (µMol)8.46571.20005.04898.5114AID1402907
Synaptojanin-2Homo sapiens (human)IC50 (µMol)6.65000.87404.137310.0000AID1620742; AID1621365; AID1634424
Polyphenol oxidase 2Agaricus bisporusKi25.00000.00063.28838.8900AID276021; AID276022
Synaptojanin-1Homo sapiens (human)IC50 (µMol)15.90001.00001.00001.0000AID1620743; AID1621366
Pancreatic triacylglycerol lipaseSus scrofa (pig)IC50 (µMol)70.00000.00401.10246.5000AID1204217
Cytochrome P450 1A1Homo sapiens (human)IC50 (µMol)15.00000.00791.24789.9000AID54202
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)150.00000.00011.774010.0000AID54221
CholinesteraseHomo sapiens (human)IC50 (µMol)2.95000.00001.559910.0000AID1493770
72 kDa type IV collagenaseHomo sapiens (human)IC50 (µMol)27.60000.00001.284810.0000AID670311
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)18.49000.00011.68479.3200AID1614268
TyrosinaseMus musculus (house mouse)IC50 (µMol)1.70000.03002.21045.2300AID1611935
TyrosinaseHomo sapiens (human)IC50 (µMol)6.79670.02304.459310.0000AID1717725; AID1717732; AID276018
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)27.13000.00053.49849.7600AID1402909
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)1.40000.00021.557410.0000AID332217
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)109.00000.00010.995010.0000AID332218
Low molecular weight protein-tyrosine phosphatase AMycobacterium tuberculosis H37RvIC50 (µMol)67.23002.74005.39678.8000AID1402908
Cytochrome P450 1B1Homo sapiens (human)IC50 (µMol)34.00000.00130.86969.9000AID1306443; AID54233
Tyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)IC50 (µMol)31.45001.10004.69009.5400AID1402911
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
serine/threonine-protein kinase 33 isoform aHomo sapiens (human)EC50 (µMol)9.65700.769114.609644.8900AID2821
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (395)

Processvia Protein(s)Taxonomy
phosphatidylinositol biosynthetic processSynaptojanin-2Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processSynaptojanin-2Homo sapiens (human)
synaptic vesicle endocytosisSynaptojanin-2Homo sapiens (human)
membrane organizationSynaptojanin-2Homo sapiens (human)
phosphatidylinositol dephosphorylationSynaptojanin-2Homo sapiens (human)
phosphatidylinositol biosynthetic processSynaptojanin-1Homo sapiens (human)
neurotransmitter transportSynaptojanin-1Homo sapiens (human)
learningSynaptojanin-1Homo sapiens (human)
synaptic vesicle primingSynaptojanin-1Homo sapiens (human)
synaptic vesicle uncoatingSynaptojanin-1Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processSynaptojanin-1Homo sapiens (human)
inositol phosphate metabolic processSynaptojanin-1Homo sapiens (human)
phosphatidylinositol metabolic processSynaptojanin-1Homo sapiens (human)
phosphatidylinositol dephosphorylationSynaptojanin-1Homo sapiens (human)
synaptic vesicle endocytosisSynaptojanin-1Homo sapiens (human)
synaptic vesicle transportSynaptojanin-1Homo sapiens (human)
membrane organizationSynaptojanin-1Homo sapiens (human)
positive regulation of endosome organizationSynaptojanin-1Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1A1Homo sapiens (human)
response to hypoxiaCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
lipid hydroxylationCytochrome P450 1A1Homo sapiens (human)
fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid metabolic processCytochrome P450 1A1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A1Homo sapiens (human)
amine metabolic processCytochrome P450 1A1Homo sapiens (human)
response to nematodeCytochrome P450 1A1Homo sapiens (human)
response to herbicideCytochrome P450 1A1Homo sapiens (human)
ethylene metabolic processCytochrome P450 1A1Homo sapiens (human)
coumarin metabolic processCytochrome P450 1A1Homo sapiens (human)
flavonoid metabolic processCytochrome P450 1A1Homo sapiens (human)
response to iron(III) ionCytochrome P450 1A1Homo sapiens (human)
insecticide metabolic processCytochrome P450 1A1Homo sapiens (human)
dibenzo-p-dioxin catabolic processCytochrome P450 1A1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
response to foodCytochrome P450 1A1Homo sapiens (human)
response to lipopolysaccharideCytochrome P450 1A1Homo sapiens (human)
response to vitamin ACytochrome P450 1A1Homo sapiens (human)
response to immobilization stressCytochrome P450 1A1Homo sapiens (human)
vitamin D metabolic processCytochrome P450 1A1Homo sapiens (human)
retinol metabolic processCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
9-cis-retinoic acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
camera-type eye developmentCytochrome P450 1A1Homo sapiens (human)
nitric oxide metabolic processCytochrome P450 1A1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1A1Homo sapiens (human)
digestive tract developmentCytochrome P450 1A1Homo sapiens (human)
tissue remodelingCytochrome P450 1A1Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A1Homo sapiens (human)
response to hyperoxiaCytochrome P450 1A1Homo sapiens (human)
maternal process involved in parturitionCytochrome P450 1A1Homo sapiens (human)
hepatocyte differentiationCytochrome P450 1A1Homo sapiens (human)
cellular response to copper ionCytochrome P450 1A1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleCytochrome P450 1A1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1A1Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
angiogenesis72 kDa type IV collagenaseHomo sapiens (human)
ovarian follicle development72 kDa type IV collagenaseHomo sapiens (human)
ovulation from ovarian follicle72 kDa type IV collagenaseHomo sapiens (human)
luteinization72 kDa type IV collagenaseHomo sapiens (human)
blood vessel maturation72 kDa type IV collagenaseHomo sapiens (human)
intramembranous ossification72 kDa type IV collagenaseHomo sapiens (human)
proteolysis72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of cell adhesion72 kDa type IV collagenaseHomo sapiens (human)
heart development72 kDa type IV collagenaseHomo sapiens (human)
embryo implantation72 kDa type IV collagenaseHomo sapiens (human)
parturition72 kDa type IV collagenaseHomo sapiens (human)
response to xenobiotic stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to mechanical stimulus72 kDa type IV collagenaseHomo sapiens (human)
peripheral nervous system axon regeneration72 kDa type IV collagenaseHomo sapiens (human)
response to activity72 kDa type IV collagenaseHomo sapiens (human)
protein metabolic process72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix disassembly72 kDa type IV collagenaseHomo sapiens (human)
protein catabolic process72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of cell migration72 kDa type IV collagenaseHomo sapiens (human)
collagen catabolic process72 kDa type IV collagenaseHomo sapiens (human)
response to retinoic acid72 kDa type IV collagenaseHomo sapiens (human)
cellular response to reactive oxygen species72 kDa type IV collagenaseHomo sapiens (human)
response to nicotine72 kDa type IV collagenaseHomo sapiens (human)
endodermal cell differentiation72 kDa type IV collagenaseHomo sapiens (human)
response to hydrogen peroxide72 kDa type IV collagenaseHomo sapiens (human)
response to estrogen72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of vasoconstriction72 kDa type IV collagenaseHomo sapiens (human)
ephrin receptor signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
macrophage chemotaxis72 kDa type IV collagenaseHomo sapiens (human)
response to electrical stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to hyperoxia72 kDa type IV collagenaseHomo sapiens (human)
face morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
bone trabecula formation72 kDa type IV collagenaseHomo sapiens (human)
prostate gland epithelium morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
cellular response to amino acid stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to interleukin-172 kDa type IV collagenaseHomo sapiens (human)
cellular response to estradiol stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to UV-A72 kDa type IV collagenaseHomo sapiens (human)
cellular response to fluid shear stress72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
response to amyloid-beta72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix organization72 kDa type IV collagenaseHomo sapiens (human)
response to hypoxia72 kDa type IV collagenaseHomo sapiens (human)
tissue remodeling72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
melanin biosynthetic process from tyrosineTyrosinaseHomo sapiens (human)
eye pigment biosynthetic processTyrosinaseHomo sapiens (human)
visual perceptionTyrosinaseHomo sapiens (human)
cell population proliferationTyrosinaseHomo sapiens (human)
response to UVTyrosinaseHomo sapiens (human)
response to blue lightTyrosinaseHomo sapiens (human)
response to vitamin DTyrosinaseHomo sapiens (human)
melanin biosynthetic processTyrosinaseHomo sapiens (human)
thymus developmentTyrosinaseHomo sapiens (human)
response to cAMPTyrosinaseHomo sapiens (human)
pigmentationTyrosinaseHomo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
symbiont-mediated suppression of host apoptosisLow molecular weight protein-tyrosine phosphatase AMycobacterium tuberculosis H37Rv
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
regulation of epidermal growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
tissue regenerationTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
cellular response to epidermal growth factor stimulusTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
negative regulation of ERBB signaling pathwayTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
negative regulation of platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
lipid metabolic processTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
autophagyTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of autophagyTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of gene expressionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of gene expressionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
T cell differentiationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of type I interferon productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
response to lipopolysaccharideTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of interleukin-6 productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of interleukin-8 productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of tumor necrosis factor productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of natural killer cell proliferationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of toll-like receptor 3 signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of toll-like receptor 4 signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
phosphoanandamide dephosphorylationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of innate immune responseTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of B cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of T cell activationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cellular response to muramyl dipeptideTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of non-canonical NF-kappaB signal transductionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of protein K63-linked ubiquitinationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of p38MAPK cascadeTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (97)

Processvia Protein(s)Taxonomy
RNA bindingSynaptojanin-2Homo sapiens (human)
phosphatidylinositol-3-phosphate phosphatase activitySynaptojanin-2Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate 5-phosphatase activitySynaptojanin-2Homo sapiens (human)
protein bindingSynaptojanin-2Homo sapiens (human)
phosphatidylinositol phosphate 4-phosphatase activitySynaptojanin-2Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 5-phosphatase activitySynaptojanin-2Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 3-phosphatase activitySynaptojanin-2Homo sapiens (human)
SH3 domain bindingSynaptojanin-2Homo sapiens (human)
PDZ domain bindingSynaptojanin-2Homo sapiens (human)
RNA bindingSynaptojanin-1Homo sapiens (human)
phosphatidylinositol-3-phosphate phosphatase activitySynaptojanin-1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate 5-phosphatase activitySynaptojanin-1Homo sapiens (human)
protein bindingSynaptojanin-1Homo sapiens (human)
phosphatidylinositol phosphate 5-phosphatase activitySynaptojanin-1Homo sapiens (human)
phosphatidylinositol phosphate 4-phosphatase activitySynaptojanin-1Homo sapiens (human)
phosphatidylinositol-4-phosphate phosphatase activitySynaptojanin-1Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 5-phosphatase activitySynaptojanin-1Homo sapiens (human)
phosphatidylinositol-3,5-bisphosphate 3-phosphatase activitySynaptojanin-1Homo sapiens (human)
inositol-1,4,5-trisphosphate 5-phosphatase activitySynaptojanin-1Homo sapiens (human)
SH3 domain bindingSynaptojanin-1Homo sapiens (human)
monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
iron ion bindingCytochrome P450 1A1Homo sapiens (human)
protein bindingCytochrome P450 1A1Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activity, acting on diphenols and related substances as donorsCytochrome P450 1A1Homo sapiens (human)
flavonoid 3'-monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxygen bindingCytochrome P450 1A1Homo sapiens (human)
enzyme bindingCytochrome P450 1A1Homo sapiens (human)
heme bindingCytochrome P450 1A1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 1A1Homo sapiens (human)
demethylase activityCytochrome P450 1A1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 1A1Homo sapiens (human)
aromatase activityCytochrome P450 1A1Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
fibronectin binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
metalloendopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
serine-type endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
protein binding72 kDa type IV collagenaseHomo sapiens (human)
metallopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
zinc ion binding72 kDa type IV collagenaseHomo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
tyrosinase activityTyrosinaseHomo sapiens (human)
copper ion bindingTyrosinaseHomo sapiens (human)
protein bindingTyrosinaseHomo sapiens (human)
identical protein bindingTyrosinaseHomo sapiens (human)
protein homodimerization activityTyrosinaseHomo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
protein tyrosine phosphatase activityLow molecular weight protein-tyrosine phosphatase AMycobacterium tuberculosis H37Rv
phosphoprotein phosphatase activityTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
SH3 domain bindingTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
phosphatase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
SH3 domain bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
kinase bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
ubiquitin protein ligase bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (72)

Processvia Protein(s)Taxonomy
cytosolSynaptojanin-2Homo sapiens (human)
cytoskeletonSynaptojanin-2Homo sapiens (human)
plasma membraneSynaptojanin-2Homo sapiens (human)
cell projectionSynaptojanin-2Homo sapiens (human)
membrane raftSynaptojanin-2Homo sapiens (human)
perinuclear region of cytoplasmSynaptojanin-2Homo sapiens (human)
presynapseSynaptojanin-2Homo sapiens (human)
microtubuleSynaptojanin-1Homo sapiens (human)
cytosolSynaptojanin-1Homo sapiens (human)
vesicle membraneSynaptojanin-1Homo sapiens (human)
terminal boutonSynaptojanin-1Homo sapiens (human)
perinuclear region of cytoplasmSynaptojanin-1Homo sapiens (human)
synaptic membraneSynaptojanin-1Homo sapiens (human)
presynapseSynaptojanin-1Homo sapiens (human)
membrane coatSynaptojanin-1Homo sapiens (human)
clathrin coat of coated pitSynaptojanin-1Homo sapiens (human)
perinuclear region of cytoplasmSynaptojanin-1Homo sapiens (human)
presynapseSynaptojanin-1Homo sapiens (human)
mitochondrial inner membraneCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular region72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
nucleus72 kDa type IV collagenaseHomo sapiens (human)
mitochondrion72 kDa type IV collagenaseHomo sapiens (human)
plasma membrane72 kDa type IV collagenaseHomo sapiens (human)
sarcomere72 kDa type IV collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytoplasmTyrosinaseHomo sapiens (human)
lysosomeTyrosinaseHomo sapiens (human)
Golgi-associated vesicleTyrosinaseHomo sapiens (human)
melanosome membraneTyrosinaseHomo sapiens (human)
melanosomeTyrosinaseHomo sapiens (human)
intracellular membrane-bounded organelleTyrosinaseHomo sapiens (human)
perinuclear region of cytoplasmTyrosinaseHomo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
cytosolLow molecular weight protein-tyrosine phosphatase AMycobacterium tuberculosis H37Rv
podosomeTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
focal adhesionTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
cell projectionTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (88)

Assay IDTitleYearJournalArticle
AID1372028Antioxidant activity assessed as relative scavenging rate constant for photolysis-induced peroxyl scavenging activity by measuring Kaox/Kst ratio using CYPMPO spin trap by ESR spectroscopic method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Resveratrol analogues like piceatannol are potent antioxidants as quantitatively demonstrated through the high scavenging ability against reactive oxygen species and methyl radical.
AID1717725Inhibition of human HMV-II cell derived tyrosinase using DOPA as substrate incubated for 5 mins by light absorbance method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations.
AID332219Inhibition of DMBA-induced preneoplastic lesions in mouse mammary gland organ culture at 10 ug/mL2002Journal of natural products, Feb, Volume: 65, Issue:2
Constituents of the bark and twigs of Artocarpus dadah with cyclooxygenase inhibitory activity.
AID276027Cytotoxicity against human BC cells at 20 ug/ml2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent.
AID1256163Inhibition of Quorum sensing system in Chromobacterium violaceum CV026 assessed as inhibition of violacein synthesis at 25 to 150 uM after 18 hrs by spectrophotometric assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
The quorum-sensing inhibiting effects of stilbenoids and their potential structure-activity relationship.
AID1256180Decrease in lasI gene expression in Pseudomonas aeruginosa PAO1 at 400 uM by RT-PCR analysis relative to control2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
The quorum-sensing inhibiting effects of stilbenoids and their potential structure-activity relationship.
AID1372027Antioxidant activity assessed as relative scavenging rate constant for photolysis-induced alkoxyl scavenging activity by measuring Kaox/Kst ratio using DMPO spin trap by ESR spectroscopic method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Resveratrol analogues like piceatannol are potent antioxidants as quantitatively demonstrated through the high scavenging ability against reactive oxygen species and methyl radical.
AID1372019Antioxidant activity assessed as Trolox equivalents of photolysis-induced hydroxyl radical scavenging activity using DMPO spin trap by ESR spectroscopic method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Resveratrol analogues like piceatannol are potent antioxidants as quantitatively demonstrated through the high scavenging ability against reactive oxygen species and methyl radical.
AID1781723Antibacterial activity against Enterococcus NR 31884 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1781722Antibacterial activity against Klebsiella pneumoniae BAA-1705 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID54204Selectivity ratio for Cytochrome P450 1B1 compared to Cytochrome P450 1A12002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors.
AID482994Inhibition of amyloid beta 25-35 fibril formation at 10 uM by using UV-visible measurements and electron microscopy analysis2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
New stilbene dimers against amyloid fibril formation.
AID1372029Antioxidant activity assessed as relative scavenging rate constant for photolysis-induced super-oxide anion scavenging activity by measuring Kaox/Kst ratio using CYPMPO spin trap by ESR spectroscopic method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Resveratrol analogues like piceatannol are potent antioxidants as quantitatively demonstrated through the high scavenging ability against reactive oxygen species and methyl radical.
AID1256179Antibacterial activity in Pseudomonas aeruginosa PAO1 for 16 hrs2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
The quorum-sensing inhibiting effects of stilbenoids and their potential structure-activity relationship.
AID1493770Inhibition of BChE (unknown origin) using thiocholine as substrate preincubated for 15 mins followed by substrate addition measured after 5 mins by Ellman's method2018European journal of medicinal chemistry, Jan-01, Volume: 1432-Arylbenzofurans from Artocarpus lakoocha and methyl ether analogs with potent cholinesterase inhibitory activity.
AID1781721Antibacterial activity against Acinetobacter baumannii BAA 1605 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID670317Inhibition of human recombinant MMP2 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Natural products as a gold mine for selective matrix metalloproteinases inhibitors.
AID1256183Decrease in rhIR gene expression in Pseudomonas aeruginosa PAO1 at 400 uM by RT-PCR analysis2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
The quorum-sensing inhibiting effects of stilbenoids and their potential structure-activity relationship.
AID1781724Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1372020Antioxidant activity assessed as Trolox equivalents of photolysis-induced methyl radical scavenging activity using DMPO spin trap by ESR spectroscopic method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Resveratrol analogues like piceatannol are potent antioxidants as quantitatively demonstrated through the high scavenging ability against reactive oxygen species and methyl radical.
AID1256164Inhibition of Quorum sensing system in Pseudomonas aeruginosa PAO1 assessed as inhibition of swarming motility at 100 uM after 16 hrs2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
The quorum-sensing inhibiting effects of stilbenoids and their potential structure-activity relationship.
AID670313Inhibition of human recombinant MMP9 catalytic domain incubated for 20 mins by fluorimetric assay2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Natural products as a gold mine for selective matrix metalloproteinases inhibitors.
AID670311Inhibition of human recombinant MMP2 catalytic domain incubated for 20 mins by fluorimetric assay2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Natural products as a gold mine for selective matrix metalloproteinases inhibitors.
AID1493772Inhibition of electric eel AChE at 0.1 mg/ml using acetylthiocholine as substrate preincubated for 15 mins followed by substrate addition measured after 5 mins by Ellman's method2018European journal of medicinal chemistry, Jan-01, Volume: 1432-Arylbenzofurans from Artocarpus lakoocha and methyl ether analogs with potent cholinesterase inhibitory activity.
AID1256175Inhibition of Quorum sensing system in Pseudomonas aeruginosa PAO1 assessed as inhibition of pyocyanin production at sub-MIC concentration after 16 to 18 hrs by spectrophotometric assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
The quorum-sensing inhibiting effects of stilbenoids and their potential structure-activity relationship.
AID1781719Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID1614268Inhibition of human 5-LOX using arachidonic acid as substrate measured after 10 mins by ELISA2019Bioorganic & medicinal chemistry, 02-15, Volume: 27, Issue:4
Design, synthesis and identification of novel coumaperine derivatives for inhibition of human 5-LOX: Antioxidant, pseudoperoxidase and docking studies.
AID1256165Inhibition of Quorum sensing system in Chromobacterium violaceum CV026 at 1 to 4 mg/ml after 24 hrs by agar-well diffusion method2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
The quorum-sensing inhibiting effects of stilbenoids and their potential structure-activity relationship.
AID332218Inhibition of COX22002Journal of natural products, Feb, Volume: 65, Issue:2
Constituents of the bark and twigs of Artocarpus dadah with cyclooxygenase inhibitory activity.
AID1717732Inhibition of human tyrosinase expressed in HEK293 cells using L-tyrosine and DOPA as substrate2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Advances in the Design of Genuine Human Tyrosinase Inhibitors for Targeting Melanogenesis and Related Pigmentations.
AID1070113Allosteric modulation of rat GABAA alpha1beta2gamma2S receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride ion current at holding potential -70 mV at 100 uM by two-microelectrode voltage clamp assay relative to GA2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Identification of dihydrostilbenes in Pholidota chinensis as a new scaffold for GABAA receptor modulators.
AID1402907Inhibition of Mycobacterium tuberculosis PtpB using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1204217Inhibition of porcine pancreatic lipase using p-nitrophenylbutyrate as substrate assessed as formation of p-nitrophenol preincubated for 15 mins followed by substrate addition measured after 15 mins2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Pancreatic lipase inhibitory constituents from Morus alba leaves and optimization for extraction conditions.
AID54233Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1B12002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors.
AID1372030Antioxidant activity assessed as relative scavenging rate constant for photolysis-induced singlet oxygen scavenging activity by measuring Kaox/Kst ratio using 4-HO-TEMP spin trap by ESR spectroscopic method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Resveratrol analogues like piceatannol are potent antioxidants as quantitatively demonstrated through the high scavenging ability against reactive oxygen species and methyl radical.
AID1372024Antioxidant activity assessed as Trolox equivalents of photolysis-induced singlet oxygen scavenging activity using 4-HO-TEMP spin trap by ESR spectroscopic method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Resveratrol analogues like piceatannol are potent antioxidants as quantitatively demonstrated through the high scavenging ability against reactive oxygen species and methyl radical.
AID1372026Antioxidant activity assessed as relative scavenging rate constant for photolysis-induced methyl radical scavenging activity by measuring Kaox/Kst ratio using DMPO spin trap by ESR spectroscopic method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Resveratrol analogues like piceatannol are potent antioxidants as quantitatively demonstrated through the high scavenging ability against reactive oxygen species and methyl radical.
AID1372023Antioxidant activity assessed as Trolox equivalents of photolysis-induced superoxide anion scavenging activity using CYPMPO spin trap by ESR spectroscopic method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Resveratrol analogues like piceatannol are potent antioxidants as quantitatively demonstrated through the high scavenging ability against reactive oxygen species and methyl radical.
AID1402914Selectivity index, ratio of IC50 for PTP-PEST (unknown origin) to IC50 for Mycobacterium tuberculosis PtpB2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1204216Inhibition of porcine pancreatic lipase using p-nitrophenylbutyrate as substrate assessed as formation of p-nitrophenol at 100 uM preincubated for 15 mins followed by substrate addition measured after 15 mins relative to control2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Pancreatic lipase inhibitory constituents from Morus alba leaves and optimization for extraction conditions.
AID54225Selectivity ratio for Cytochrome P450 1B1 compared to Cytochrome P450 1A22002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors.
AID1402909Inhibition of human PTP1B using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1372022Antioxidant activity assessed as Trolox equivalents of photolysis-induced peroxyl scavenging activity using CYPMPO spin trap by ESR spectroscopic method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Resveratrol analogues like piceatannol are potent antioxidants as quantitatively demonstrated through the high scavenging ability against reactive oxygen species and methyl radical.
AID1256177Antibacterial activity in Pseudomonas aeruginosa PAO1 at 400 uM measured every 2 hrs for 24 hrs by microplate reader analysis2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
The quorum-sensing inhibiting effects of stilbenoids and their potential structure-activity relationship.
AID276021Inhibition of mushroom tyrosinase at 9.2 uM2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent.
AID54221Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes expressing human cytochrome P450 1A22002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors.
AID1256182Decrease in rhII gene expression in Pseudomonas aeruginosa PAO1 at 400 uM by RT-PCR analysis2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
The quorum-sensing inhibiting effects of stilbenoids and their potential structure-activity relationship.
AID276028Cytotoxicity against human NCI-H187 cells at 20 ug/ml2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent.
AID276017Inhibition of tyrosinase at 100 uM2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent.
AID1372025Antioxidant activity assessed as relative scavenging rate constant for photolysis-induced hydroxyl radical scavenging activity by measuring Kaox/Kst ratio using DMPO spin trap by ESR spectroscopic method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Resveratrol analogues like piceatannol are potent antioxidants as quantitatively demonstrated through the high scavenging ability against reactive oxygen species and methyl radical.
AID1781720Antibacterial activity against Escherichia coli ATCC 25922 assessed as bacterial growth inhibition incubated for 16 to 18 hrs by broth microdilution method
AID54202Inhibition of ethoxyresorufin O-deethylation (EROD) in bicistronic bacterial membranes epressing human cytochrome P450 1A12002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors.
AID1256181Decrease in lasR gene expression in Pseudomonas aeruginosa PAO1 at 400 uM by RT-PCR analysis2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
The quorum-sensing inhibiting effects of stilbenoids and their potential structure-activity relationship.
AID276018Inhibition of tyrosinase2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent.
AID1306443Inhibition of recombinant human CYP1B1 expressed in Escherichia coli DH5aplha cells assessed as O-deethylation of ethoxyresorufin in presence of NADPH measured after 2 mins by spectrofluorometric method2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Aryl morpholino triazenes inhibit cytochrome P450 1A1 and 1B1.
AID1402911Inhibition of LYP (unknown origin) using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1402913Inhibition of PTP-PEST (unknown origin) using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1256174Inhibition of Quorum sensing system in Chromobacterium violaceum CV026 assessed as inhibition of violacein synthesis at 150 uM after 18 hrs by spectrophotometric assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
The quorum-sensing inhibiting effects of stilbenoids and their potential structure-activity relationship.
AID670312Inhibition of human recombinant MMP3 catalytic domain incubated for 20 mins by fluorimetric assay2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Natural products as a gold mine for selective matrix metalloproteinases inhibitors.
AID1372021Antioxidant activity assessed as Trolox equivalents of photolysis-induced alkoxyl scavenging activity using DMPO spin trap by ESR spectroscopic method2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Resveratrol analogues like piceatannol are potent antioxidants as quantitatively demonstrated through the high scavenging ability against reactive oxygen species and methyl radical.
AID1256176Inhibition of Quorum sensing system in Pseudomonas aeruginosa PAO1 assessed as inhibition of pyocyanin production at 400 uM after 16 to 18 hrs by spectrophotometric assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
The quorum-sensing inhibiting effects of stilbenoids and their potential structure-activity relationship.
AID1402908Inhibition of Mycobacterium tuberculosis PtpA using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID670314Inhibition of human recombinant MMP12 catalytic domain incubated for 20 mins by fluorimetric assay2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Natural products as a gold mine for selective matrix metalloproteinases inhibitors.
AID670310Inhibition of human recombinant MMP1 catalytic domain incubated for 20 mins by fluorimetric assay2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Natural products as a gold mine for selective matrix metalloproteinases inhibitors.
AID276022Inhibition of mushroom tyrosinase at 18.4 uM2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent.
AID1402906Selectivity index, ratio of IC50 for Mycobacterium tuberculosis PtpA to IC50 for Mycobacterium tuberculosis PtpB2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1256178Antibacterial activity in Chromobacterium violaceum CV026 for 16 hrs2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
The quorum-sensing inhibiting effects of stilbenoids and their potential structure-activity relationship.
AID1611935Inhibition of tyrosinase in mouse B16 cells2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Inhibitors of Melanogenesis: An Updated Review.
AID1402910Selectivity index, ratio of IC50 for human PTP1B to IC50 for Mycobacterium tuberculosis PtpB2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1402912Selectivity index, ratio of IC50 for LYP (unknown origin) to IC50 for Mycobacterium tuberculosis PtpB2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID332217Inhibition of COX12002Journal of natural products, Feb, Volume: 65, Issue:2
Constituents of the bark and twigs of Artocarpus dadah with cyclooxygenase inhibitory activity.
AID276026Cytotoxicity against human KB cells at 20 ug/ml2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent.
AID670315Inhibition of human recombinant MMP13 catalytic domain incubated for 20 mins by fluorimetric assay2012Bioorganic & medicinal chemistry, Jul-01, Volume: 20, Issue:13
Natural products as a gold mine for selective matrix metalloproteinases inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (148)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (1.35)18.7374
1990's0 (0.00)18.2507
2000's21 (14.19)29.6817
2010's89 (60.14)24.3611
2020's36 (24.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.68%)5.53%
Reviews3 (2.03%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other144 (97.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]